GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (NAS:VALN) » Definitions » EV-to-EBIT

Valneva SE (Valneva SE) EV-to-EBIT

: -8.07 (As of Today)
View and export this data going back to 2021. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Valneva SE's Enterprise Value is $654.0 Mil. Valneva SE's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-81.1 Mil. Therefore, Valneva SE's EV-to-EBIT for today is -8.07.

The historical rank and industry rank for Valneva SE's EV-to-EBIT or its related term are showing as below:

VALN' s EV-to-EBIT Range Over the Past 10 Years
Min: -90.53   Med: -12.06   Max: 249.41
Current: -8.14

During the past 13 years, the highest EV-to-EBIT of Valneva SE was 249.41. The lowest was -90.53. And the median was -12.06.

VALN's EV-to-EBIT is ranked worse than
100% of 441 companies
in the Biotechnology industry
Industry Median: 8.62 vs VALN: -8.14

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Valneva SE's Enterprise Value for the quarter that ended in Dec. 2023 was $809.8 Mil. Valneva SE's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-81.1 Mil. Valneva SE's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -10.01%.


Valneva SE EV-to-EBIT Historical Data

The historical data trend for Valneva SE's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 144.15 -11.08 -44.18 -5.78 -9.80

Valneva SE Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.78 -4.79 163.86 -7.91 -9.80

Competitive Comparison

For the Biotechnology subindustry, Valneva SE's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valneva SE EV-to-EBIT Distribution

For the Biotechnology industry and Healthcare sector, Valneva SE's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Valneva SE's EV-to-EBIT falls into.



Valneva SE EV-to-EBIT Calculation

Valneva SE's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=654.038/-81.089
=-8.07

Valneva SE's current Enterprise Value is $654.0 Mil.
Valneva SE's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-81.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Valneva SE  (NAS:VALN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Valneva SE's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-81.089/809.7703491
=-10.01 %

Valneva SE's Enterprise Value for the quarter that ended in Dec. 2023 was $809.8 Mil.
Valneva SE's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-81.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Valneva SE EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Valneva SE's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Valneva SE (Valneva SE) Business Description

Traded in Other Exchanges
Address
6 Rue Alain Bombard, Saint-Herblain, FRA, 44800
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, & third-party products; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The majority is from the Commercialized vaccines segment & geographically from the United States.